Jon Congleton - 17 Mar 2023 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
Chief Executive Officer, Director
Signature
/s/ Adam Levy, Attorney-in-fact
Issuer symbol
MLYS
Transactions as of
17 Mar 2023
Net transactions value
$0
Form type
4
Filing time
21 Mar 2023, 18:48:09 UTC
Previous filing
09 Feb 2023
Next filing
11 Aug 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLYS Stock Option Award $0 +99,800 $0.000000 99,800 17 Mar 2023 Common Stock 99,800 $15.44 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter.